Omnimmune Holdings, Inc. is engaged in the provision of cancer therapeutic, diagnostic and prognostic technologies. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2007-12-19. The firm is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
최신 재무제표(Form-10K)에 따르면, Kinetic Development Group Ltd의 총 자산은 $0이며, 순손실입니다.
OMMH의 주요 재무 비율은 무엇인가요?
Kinetic Development Group Ltd의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Omnimmune Holdings Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Kinetic Development Group Ltd 주요 수익원은 Coal Mining이며, 최신 수익 발표에서 수익은 4,895,618,910입니다. 지역별로는 China이 Kinetic Development Group Ltd의 주요 시장이며, 수익은 5,730,091,346입니다.
Omnimmune Holdings Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Kinetic Development Group Ltd의 순손실은 $0입니다.